Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 5Gynecologic 5Gastrointestinal 5Breast 4Sarcoma 3Genitourinary 3Tumor-Agnostic 2Plasma cell 1Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × saracatinib × Tumor-Agnostic × Clear all
NCT02085603 2018-04-13

SarCaBon

Sheffield Teaching Hospitals NHS Foundation Trust

Phase 2 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT00496028 2010-09-22

Phase I Study in Patients With Solid Tumours

AstraZeneca

Phase 1 Completed
148 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡